Dyadic International, Inc. (DYAI)
NasdaqCM
Fundamentals
Valuation and ratings
Dyadic International, Inc. trades at USD1.19. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Dyadic International, Inc.
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Super investor ownership
1 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$67.0K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own DYAI?
1 of the institutions we track reported a position in DYAI in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for DYAI, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.